University of Arizona
Tucson, Arizona, 85711, United States
NCT Number: NCT06931886
This study is examining the effects of six weeks of inspiratory muscle strength training (IMST) on outcomes related to pulmonary hypertension. This study leverages previous cardiopulmonary exercise test (CPET) results and a pre-existing upcoming CPET to examine the effects of IMST on cardiopulmonary pressures and exercise tolerance and ability.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Tucson, Arizona, 85711, United States
PH is a condition characterized by abnormally high blood pressure in the lungs (i.e., pulmonary arterial pressure), which impacts heart function and reduces exercise tolerance. This study will assess whether six weeks of a breathing exercise called IMST can improve heart and lung function as well as exercise capacity for individuals with PH.
For this study, patients will be asked to perform IMST for the six weeks prior to their next scheduled clinical standard of care assessment of their PH. The goal of this study is to determine whether IMST reduces pulmonary arterial pressure and improves exercise tolerance in individuals with PH. This study will be minimally invasive, as it simply adds a safe, well-tolerated, non-invasive respiratory training to the participants' standard of care and leverages their existing PH assessment data to evaluate the impact of IMST on PH.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will be asked to inhale against a resistance. This resistance will be set to ~55% of their maximal inspiratory ability. Participants will complete 5 sets of 6 breaths (30 total) a day for 5 days a week for 6 weeks.
Other names: IMST, Resisted Breathing Training, Resisted Inspiratory Efforts
Time frame: The data will be obtained from previous medical records of patient visits occurring up to 8 months prior to enrollment and at the end of treatment at 6 weeks post enrollment. .
To be eligible for this study, patients must already have an upcoming invasive cardiopulmonary exercise test scheduled for assessment of their PH. Pulmonary arterial pressure will be obtained from this upcoming appointment as well as from previous medical records and an upcoming already scheduled assessment of pulmonary hypertension.
Time frame: The data will be obtained from previous medical records of patient visits occurring up to 8 months prior to enrollment and at the end of treatment, which occurs 6 weeks post-initiation.
This will be obtained as part of the usual standard assessment of pulmonary hypertension. Patients must already have this scheduled prior to enrollment in this study. Cardiac output, a measure of the volume of blood the heart pumps per minute, will be determined at rest and in response to exercise during the scheduled cardiopulmonary exercise test. This involves a graded maximal cycling protocol on a stationary bike, where resistance progressively increases until the patient reaches their maximum effort or exhaustion .
Time frame: The data will be obtained from previous medical records of patient visits occurring up to 8 months prior to enrollment and at the end of treatment at 6 weeks post enrollment. .
This will be obtained as part of the usual standard assessment of pulmonary hypertension. Patients must already have this scheduled prior to enrollment in this study. Maximal oxygen uptake, a measure of the body's maximum ability to take in, transport, and utilize oxygen during intense exercise, will be determined during the scheduled cardiopulmonary exercise test. This test involves a graded maximal cycling protocol on a stationary bike, where resistance progressively increases until the patient reaches their maximum effort or exhaustion. Throughout the test, patients will wear a mask that is used to analyze gas exchange.
University of Arizona
Other
Effects of Inspiratory Muscle Strength Training on Pulmonary Hypertension: A Six Week Study
Acronym: PHIT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07445347
Bevacizumab, Cardiovascular Abnormalities
Poitiers, France
View Trial DetailsNCT03683186
Cardiovascular Diseases, Connective Tissue Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT01725763
Cardiovascular Diseases, Elevated Mean Pulmonary Arterial Pressure
Graz, Styria, Austria
View Trial DetailsNCT01571700
Cardiovascular Diseases, Hypertension
Stanford, California, United States
View Trial Details